JPH11512099A - リポソーマルホスホジエステル、ホスホロチオエート、およびp−エトキシオリゴヌクレオチド - Google Patents
リポソーマルホスホジエステル、ホスホロチオエート、およびp−エトキシオリゴヌクレオチドInfo
- Publication number
- JPH11512099A JPH11512099A JP9510642A JP51064297A JPH11512099A JP H11512099 A JPH11512099 A JP H11512099A JP 9510642 A JP9510642 A JP 9510642A JP 51064297 A JP51064297 A JP 51064297A JP H11512099 A JPH11512099 A JP H11512099A
- Authority
- JP
- Japan
- Prior art keywords
- oligonucleotides
- composition
- oligonucleotide
- antisense
- liposome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/312—Phosphonates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Silicon Polymers (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.(a)中性リン脂質から本質的になるリポソームと、(b)ホスホジエステ ルオリゴヌクレオチド、ホスホロチオエートオリゴヌクレオチドおよびp−エト キシオリゴヌクレオチドとからなる群から選ばれ、リポソームに封じ込められた アンチセンスオリゴヌクレオチドを含む、アンチセンスオリゴヌクレオチドのリ ポソーム組成物。 2.リン脂質がホスファチジルコリンである、請求項1の組成物。 3.リン脂質がジオレオイルホスファチジルコリンである、請求項1の組成物。 4.アンチセンスオリゴヌクレオチドがホスホジエステルオリゴヌクレオチドで あり、オリゴに対するリン脂質のモル比が約3,000:1より低い、請求項1の組成 物。 5.アンチセンスオリゴヌクレオチドがホスホロチオエートオリゴヌクレオチド であり、リン脂質のオリゴに対するモル比が約10:1〜約50:1である、請求項1の 組成物。 6.アンチセンスオリゴヌクレオチドがp−エトキシオリゴヌクレオチドであり 、リン脂質のオリゴに対するモル比が5:1〜100:1である、請求項1の組成物。 7.アンチセンスオリゴヌクレオチドが、GAAGGGCTTCTGCGTCの 配列を有する核酸分子から本質的になるp−エトキシオリゴヌクレオチドである 、請求項1の組成物。 8.アンチセンスオリゴヌクレオチドが、CTGAAGGGCTTCTTCCの 配列を有する核酸分子から本質的になるp−エトキシオリゴヌクレオチドである 、請求項1の組成物。 9.アンチセンスオリゴヌクレオチドが、GGGCTTTTGAACTCTGC Tの配列を有する核酸分子から本質的になるp−エトキシオリゴヌクレオチドで ある、請求項1の組成物。 10.(a)中性リン脂質から本質的になるリポソームと、(b)ホスホジエステ ルオリゴヌクレオチド、ホスホロチオエートオリゴヌクレオチド、およびp−エ トキシオリゴヌクレオチドからなる群から選ばれ、リポソームに封じ込めら れたアンチセンスオリゴヌクレオチドとを含む組成物の、腫瘍細胞の増殖を抑制 しうる量を、腫瘍を持つ哺乳類へ投与する過程を含む、腫瘍細胞の増殖を抑制す る方法。 11.(a)中性のリン脂質と、ホスホジエステルオリゴヌクレオチド、ホスホロ チオエートオリゴヌクレオチドおよびp−エトキシオリゴヌクレオチドからなる 群から選ばれたアンチセンスオリゴヌクレオチドから本質的になる凍結乾燥組成 物を水和し、それによりフリーのオリゴヌクレオチドとリポソームに封じ込めら れたオリゴヌクレオチドを含む水懸濁液を形成させる過程と、 (b)透析によりフリーのオリゴヌクレオチドをリポソームから分離する過 程とを含む、アンチセンスオリゴヌクレオチドのリポソーム組成物を調製する方 法。 12.水懸濁液を透析前に超音波処理する、請求項11の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/520,385 | 1995-08-29 | ||
US08/520,385 US5855911A (en) | 1995-08-29 | 1995-08-29 | Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides |
PCT/US1996/014146 WO1997007784A2 (en) | 1995-08-29 | 1996-08-26 | LIPOSOMAL PHOSPHODIESTER, PHOSPHOROTHIOATE, AND p-ETHOXY OLIGONUCLEOTIDES |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH11512099A true JPH11512099A (ja) | 1999-10-19 |
JP4291412B2 JP4291412B2 (ja) | 2009-07-08 |
Family
ID=24072378
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51064297A Expired - Fee Related JP4291412B2 (ja) | 1995-08-29 | 1996-08-26 | リポソーマルホスホジエステル、ホスホロチオエート、およびp−エトキシオリゴヌクレオチド |
Country Status (11)
Country | Link |
---|---|
US (4) | US5855911A (ja) |
EP (1) | EP0847272B1 (ja) |
JP (1) | JP4291412B2 (ja) |
AT (1) | ATE253897T1 (ja) |
AU (1) | AU6912996A (ja) |
CA (1) | CA2228944C (ja) |
DE (1) | DE69630691T2 (ja) |
DK (1) | DK0847272T3 (ja) |
ES (1) | ES2210385T3 (ja) |
PT (1) | PT847272E (ja) |
WO (1) | WO1997007784A2 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008536874A (ja) * | 2005-04-15 | 2008-09-11 | ボード オブ リージェンツ ザ ユニバーシティー オブ テキサス システム | 中性脂質組成物によるsiRNAの送達 |
JP2009535384A (ja) * | 2006-05-03 | 2009-10-01 | サントル ナシオナル ドゥ ラ ルシェルシェサイアンティフィク(セエヌエールエス) | リポソームの即時的および可逆的濃縮のための方法 |
JP2018534361A (ja) * | 2015-10-14 | 2018-11-22 | バイオ−パス ホールディングス, インコーポレイテッド | リポソーム製剤のためのp−エトキシ核酸 |
JP2020517632A (ja) * | 2017-04-19 | 2020-06-18 | バイオ−パス ホールディングス, インコーポレイテッド | Stat3阻害のためのp−エトキシ核酸 |
JP2020517631A (ja) * | 2017-04-19 | 2020-06-18 | バイオ−パス ホールディングス, インコーポレイテッド | Igf−1r阻害のためのp−エトキシ核酸 |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5855911A (en) * | 1995-08-29 | 1999-01-05 | Board Of Regents, The University Of Texas System | Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides |
US6977244B2 (en) * | 1996-10-04 | 2005-12-20 | Board Of Regents, The University Of Texas Systems | Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides |
US6894031B1 (en) * | 1996-11-21 | 2005-05-17 | Cedars-Sinai Medical Center | Pituitary tumor transforming gene (PTTG) carboxy-terminal peptides and methods of use thereof to inhibit neoplastic cellular proliferation and/or transformation |
US6565889B2 (en) * | 1996-12-02 | 2003-05-20 | The Regents Of The University Of California | Bilayer structure which encapsulates multiple containment units and uses thereof |
US7262173B2 (en) | 1997-03-21 | 2007-08-28 | Georgetown University | Chemosensitizing with liposomes containing oligonucleotides |
US6126965A (en) * | 1997-03-21 | 2000-10-03 | Georgetown University School Of Medicine | Liposomes containing oligonucleotides |
EP1027033B1 (en) * | 1997-05-14 | 2009-07-22 | The University Of British Columbia | High efficiency encapsulation of nucleic acids in lipid vesicles |
US6835395B1 (en) | 1997-05-14 | 2004-12-28 | The University Of British Columbia | Composition containing small multilamellar oligodeoxynucleotide-containing lipid vesicles |
TWI225412B (en) * | 1997-06-23 | 2004-12-21 | Sequus Pharm Inc | Liposome-entrapped polynucleotide composition and method |
DE69834038D1 (de) * | 1997-07-01 | 2006-05-18 | Isis Pharmaceutical Inc | Zusammensetzungen und verfahren zur verabreichung von oligonukleotiden über die speiseröhre |
DE19740092A1 (de) * | 1997-09-12 | 1999-03-18 | Ulrich Dr Med Hengge | Liposomen und Verfahren zur Transfektion von Zellen |
US7285288B1 (en) * | 1997-10-03 | 2007-10-23 | Board Of Regents, The University Of Texas System | Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides |
US7704962B1 (en) * | 1997-10-03 | 2010-04-27 | Board Of Regents, The University Of Texas System | Small oligonucleotides with anti-tumor activity |
IL144975A0 (en) | 1999-02-26 | 2002-06-30 | Univ British Columbia | A composition containing an antisense oligonucleotide |
US7112337B2 (en) | 1999-04-23 | 2006-09-26 | Alza Corporation | Liposome composition for delivery of nucleic acid |
AU7868400A (en) | 1999-10-08 | 2001-04-23 | Alza Corporation | Neutral-cationic lipid for nucleic acid and drug delivery |
FR2802422B1 (fr) * | 1999-12-21 | 2002-08-09 | Capsulis | Structures mixtes resultant de l'incorporation d'une macromolecule biologique, en particulier d'adn, dans une phase structuree d'amphiphiles et vesicules obtenues a partir de ces structures |
US7569551B2 (en) | 2000-02-25 | 2009-08-04 | The University Of British Columbia | Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides |
WO2002022642A1 (en) | 2000-09-14 | 2002-03-21 | The University Of British Columbia | Antisense insulin-like growth factor binding protein (igfbp)-2-oligodeoxynucleotides for prostate and other endocrine tumor therapy |
EP1460898A4 (en) * | 2002-01-03 | 2006-05-24 | Univ Texas | OLIGONUCLEOTIDES ANTISENSE WT1 INHIBITING BREAST CANCER |
KR101166214B1 (ko) * | 2002-01-17 | 2012-07-16 | 더 유니버시티 오브 브리티쉬 콜롬비아 | 아이지에프비피-2 및 아이지에프비피-5를 억제하는 양특이성 안티센스 올리고뉴클레오티드 및 그 사용방법 |
WO2004018675A1 (en) | 2002-08-21 | 2004-03-04 | The University Of British Columbia | Treatment of melanoma by reduction in clusterin levels |
KR101142080B1 (ko) | 2002-10-02 | 2012-05-03 | 더 유니버시티 오브 브리티쉬 콜롬비아 | 전립선암 및 다른 암의 치료 방법 및 조성물 |
EP1613285A2 (en) | 2003-03-31 | 2006-01-11 | Alza Corporation | Lipid particles having asymmetric lipid coating and method of preparing same |
AU2003259832A1 (en) | 2003-08-14 | 2005-03-10 | Boston Scientific Limited | Medical slings |
CA2539727C (en) * | 2003-10-01 | 2016-11-01 | The University Of British Columbia | Bispecific oligonucleotide for the treatment of cns malignancies |
US20050112130A1 (en) | 2003-11-05 | 2005-05-26 | Bhat Neelima M. | Enhanced B cell cytotoxicity of CDIM binding antibody |
CA2546616A1 (en) | 2003-11-21 | 2005-06-09 | Alza Corporation | Gene delivery mediated by liposome-dna complex with cleavable peg surface modification |
WO2005094899A1 (en) | 2004-04-02 | 2005-10-13 | The University Of British Columbia | Clusterin antisense therapy for treatment of cancer |
CA2570305C (en) | 2004-06-14 | 2015-03-10 | Boston Scientific Scimed, Inc. | Systems, methods and devices relating to implantable supportive slings |
KR20080007425A (ko) | 2004-11-05 | 2008-01-21 | 팔링겐, 인코포레이티드 | 항체 유도된 세포막 손상 |
SI1814595T1 (sl) * | 2004-11-23 | 2014-06-30 | The University Of British Columbia | Zdravljenje raka s kombinacijo sredstva, ki moti EGF signalno pot, in oligonukleotida, ki zniĹľuje nivoje klusterina |
EP1871282B1 (en) * | 2005-04-06 | 2015-03-04 | Boston Scientific Limited | Systems and devices for treating pelvic floor disorders |
EP1909687A1 (en) | 2005-07-13 | 2008-04-16 | Boston Scientific Scimed, Inc. | Snap fit sling anchor system and related methods |
US7981023B2 (en) * | 2005-07-25 | 2011-07-19 | Boston Scientific Scimed, Inc. | Elastic sling system and related methods |
EP1909691B1 (en) | 2005-07-25 | 2015-09-16 | Boston Scientific Limited | Pelvic floor repair system |
US8273429B2 (en) * | 2006-01-19 | 2012-09-25 | Federal-Mogul World Wide, Inc. | Fabric for end fray resistance and protective sleeves formed therewith and methods of construction |
WO2008106781A1 (en) * | 2007-03-05 | 2008-09-12 | The University Of British Columbia | Treatment of squamous cell carcinoma with hsp27 antisense oligonucleotides and radiotherapy |
EP2306978A2 (en) * | 2008-06-06 | 2011-04-13 | Mirna Therapeutics, Inc. | Compositions for the in vivo delivery of rnai agents |
EP2652136B1 (en) | 2010-12-17 | 2018-11-07 | INSERM - Institut National de la Santé et de la Recherche Médicale | Nucleic acids targeting tctp for use in the treatment of chemo-or hormone-resistant cancers |
EP2741784B1 (en) | 2011-03-02 | 2017-05-17 | Board Of Regents, The University Of Texas System | Tusc2 therapies |
US9113991B2 (en) | 2011-05-12 | 2015-08-25 | Boston Scientific Scimed, Inc. | Anchors for bodily implants and methods for anchoring bodily implants into a patient's body |
US9636201B2 (en) | 2011-05-12 | 2017-05-02 | Boston Scientific Scimed, Inc. | Delivery members for delivering an implant into a body of a patient |
WO2013120012A2 (en) | 2012-02-08 | 2013-08-15 | Igm Biosciences Inc. | Cdim binding proteins and uses thereof |
CN103565745A (zh) | 2012-08-10 | 2014-02-12 | 德克萨斯州大学***董事会 | 用于治疗中风的神经保护性脂质体组合物和方法 |
WO2014195755A1 (en) | 2013-06-05 | 2014-12-11 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Hydrophobically modified antisense oligonucleotides comprising a ketal group |
WO2014195754A1 (en) | 2013-06-05 | 2014-12-11 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Hydrophobically modified antisense oligonucleotides comprising a triple alkyl chain |
CN108601765A (zh) | 2015-12-18 | 2018-09-28 | 德克萨斯州大学***董事会 | 用于早产管理的治疗剂 |
SG10201913501RA (en) * | 2016-09-14 | 2020-03-30 | Univ Nanyang Tech | Liposomal formulations |
EP3512525B1 (en) | 2016-09-16 | 2022-07-27 | Bio-Path Holdings, Inc. | Combination therapy with liposomal antisense oligonucleotides |
KR102661905B1 (ko) | 2016-10-12 | 2024-04-29 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | Tusc2 면역요법을 위한 방법 및 조성물 |
CN111447922A (zh) * | 2017-04-19 | 2020-07-24 | 拜奥-帕斯控股股份有限公司 | 用于igf-1r抑制的p-乙氧基核酸 |
JP2023522103A (ja) | 2020-04-20 | 2023-05-26 | ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム | 生物学的に活性な乾燥粉末組成物ならびにその製造および使用の方法 |
WO2022040435A1 (en) | 2020-08-19 | 2022-02-24 | The Board Of Regents Of The University Of Texas System | Nanodrugs for targeted drug delivery and use thereof |
Family Cites Families (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH621479A5 (ja) | 1977-08-05 | 1981-02-13 | Battelle Memorial Institute | |
US4394448A (en) | 1978-02-24 | 1983-07-19 | Szoka Jr Francis C | Method of inserting DNA into living cells |
US4469863A (en) | 1980-11-12 | 1984-09-04 | Ts O Paul O P | Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof |
US4480041A (en) * | 1982-07-09 | 1984-10-30 | Collaborative Research, Inc. | Use of phosphotriester intermediates for preparation of functionalized liposomes |
FR2540122B1 (fr) | 1983-01-27 | 1985-11-29 | Centre Nat Rech Scient | Nouveaux composes comportant une sequence d'oligonucleotide liee a un agent d'intercalation, leur procede de synthese et leur application |
US4721612A (en) * | 1984-04-12 | 1988-01-26 | The Liposome Company, Inc. | Steroidal liposomes |
US5202429A (en) | 1986-07-09 | 1993-04-13 | The Wistar Institute | DNA molecules having human BCL-2 gene sequences |
US5049388A (en) * | 1986-11-06 | 1991-09-17 | Research Development Foundation | Small particle aerosol liposome and liposome-drug combinations for medical use |
US5094785A (en) | 1986-12-10 | 1992-03-10 | Ciba Corning Diagnostics Corp. | Process for stabilizing liposomes |
US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US4920016A (en) | 1986-12-24 | 1990-04-24 | Linear Technology, Inc. | Liposomes with enhanced circulation time |
US5030442A (en) * | 1987-03-30 | 1991-07-09 | Liposome Technology, Inc. | Non-crystalline minoxidil composition |
US4904582A (en) | 1987-06-11 | 1990-02-27 | Synthetic Genetics | Novel amphiphilic nucleic acid conjugates |
US4950432A (en) * | 1987-10-16 | 1990-08-21 | Board Of Regents, The University Of Texas System | Polyene microlide pre-liposomal powders |
US5178875A (en) * | 1991-01-14 | 1993-01-12 | The Board Of Regents, The University Of Texas System | Liposomal-polyene preliposomal powder and method for its preparation |
US4924624A (en) * | 1987-10-22 | 1990-05-15 | Temple University-Of The Commonwealth System Of Higher Education | 2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof |
US5188897A (en) * | 1987-10-22 | 1993-02-23 | Temple University Of The Commonwealth System Of Higher Education | Encapsulated 2',5'-phosphorothioate oligoadenylates |
WO1989006977A1 (en) * | 1988-02-04 | 1989-08-10 | Board Of Regents, The University Of Texas System | Formulation and use of retinoids in treatment of cancer and other diseases |
US5098890A (en) * | 1988-11-07 | 1992-03-24 | Temple University-Of The Commonwealth System Of Higher Education | Antisence oligonucleotides to c-myb proto-oncogene and uses thereof |
US5734033A (en) * | 1988-12-22 | 1998-03-31 | The Trustees Of The University Of Pennsylvania | Antisense oligonucleotides inhibiting human bcl-2 gene expression |
US5831066A (en) | 1988-12-22 | 1998-11-03 | The Trustees Of The University Of Pennsylvania | Regulation of bcl-2 gene expression |
US5087617A (en) * | 1989-02-15 | 1992-02-11 | Board Of Regents, The University Of Texas System | Methods and compositions for treatment of cancer using oligonucleotides |
US5248671A (en) * | 1989-02-15 | 1993-09-28 | Board Of Regents, The University Of Texas System | Methods and compositions for treatment of cancer using oligonucleotides |
FR2644080A1 (fr) * | 1989-03-13 | 1990-09-14 | Trizac Jacques | Dispositif de filtration et d'evacuation de petites particules, dechets et detritus, de natures diverses |
WO1990012595A1 (en) | 1989-04-18 | 1990-11-01 | Vestar, Inc. | Liposomal targeting of ischemic tissue |
US5112962A (en) * | 1989-04-19 | 1992-05-12 | Northwestern University | Labile anchors for solid phase polynucleotide synthesis |
US5227170A (en) * | 1989-06-22 | 1993-07-13 | Vestar, Inc. | Encapsulation process |
US5100662A (en) * | 1989-08-23 | 1992-03-31 | The Liposome Company, Inc. | Steroidal liposomes exhibiting enhanced stability |
US5542935A (en) | 1989-12-22 | 1996-08-06 | Imarx Pharmaceutical Corp. | Therapeutic delivery systems related applications |
US5469854A (en) * | 1989-12-22 | 1995-11-28 | Imarx Pharmaceutical Corp. | Methods of preparing gas-filled liposomes |
WO1993007883A1 (en) * | 1991-10-24 | 1993-04-29 | Isis Pharmaceuticals, Inc. | Derivatized oligonucleotides having improved uptake and other properties |
CA2033725C (en) | 1990-01-24 | 2001-05-29 | Folker Pittrof | Pharmaceutical and cosmetic compositions containing a salt of cholanic acid |
US5279833A (en) | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
US5264618A (en) * | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
CA2081769A1 (en) * | 1990-04-30 | 1991-10-31 | Isis Pharmaceuticals Inc. | Oligonucleotide modulation of arachidonic acid metabolism |
US5665710A (en) * | 1990-04-30 | 1997-09-09 | Georgetown University | Method of making liposomal oligodeoxynucleotide compositions |
DK0464638T3 (da) | 1990-07-02 | 1997-10-13 | Hoechst Ag | Oligonukleotidanaloge med terminale 3-3- eller 5-5-internukleotidbindinger. |
US5135917A (en) * | 1990-07-12 | 1992-08-04 | Nova Pharmaceutical Corporation | Interleukin receptor expression inhibiting antisense oligonucleotides |
US5378825A (en) | 1990-07-27 | 1995-01-03 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs |
EP0556231A4 (en) * | 1990-09-17 | 1994-08-17 | Univ California | Method and composition for controlling proliferation of cells |
US5271941A (en) * | 1990-11-02 | 1993-12-21 | Cho Chung Yoon S | Antisense oligonucleotides of human regulatory subunit RI.sub.α of cAMP-dependent protein kinases |
DE4110085A1 (de) * | 1991-03-27 | 1992-10-01 | Boehringer Ingelheim Int | 2'-o-alkyl-oligoribonukleotide, verfahren zu deren herstellung und deren verwendung als antisense-oligonukleotide |
FR2677272B1 (fr) * | 1991-06-05 | 1995-03-03 | Biovecteurs As | Vecteur particulaire a tropisme selectif, procede de preparation et composition pharmaceutique. |
CA2103377A1 (en) * | 1991-06-18 | 1992-12-19 | Bruno Calabretta | Selective inhibition of leukemic cell proliferation by bcr-abl antisense oligonucleotides |
US5525719A (en) | 1991-08-30 | 1996-06-11 | Chemgenes Corporation | N-protected-2'-O-methyl-and N-protected-3'-O-methyl-ribonucleosides and their phosphoramidite derivatives |
AU675923B2 (en) * | 1991-12-04 | 1997-02-27 | E.I. Du Pont De Nemours And Company | Fatty acid desaturase genes from plants |
US5279957A (en) * | 1992-04-30 | 1994-01-18 | Washington University | cDNA encoding human phospholipase A2 polypeptide |
IL105914A0 (en) * | 1992-06-04 | 1993-10-20 | Univ California | Methods and compositions for in vivo gene therapy |
US5320962A (en) * | 1992-07-22 | 1994-06-14 | Duke University | DNA encoding the human A1 adenosine receptor |
NL9201440A (nl) * | 1992-08-11 | 1994-03-01 | Univ Leiden | Triantennaire clusterglycosiden, hun bereiding en toepassing. |
WO1994005259A1 (en) * | 1992-09-02 | 1994-03-17 | Georgetown University | Method of encapsulating anthracycline glycosides in liposomes |
US6001992A (en) | 1999-01-07 | 1999-12-14 | Isis Pharmaceuticals Inc. | Antisense modulation of novel anti-apoptotic bcl-2-related proteins |
EP0668782B1 (en) | 1992-10-21 | 2001-04-11 | Temple University - Of The Commonwealth System Of Higher Education | Combination of antineoplastic agent and antisense oligonucleotides for treatment of cancer |
US6015886A (en) | 1993-05-24 | 2000-01-18 | Chemgenes Corporation | Oligonucleotide phosphate esters |
US5417978A (en) * | 1993-07-29 | 1995-05-23 | Board Of Regents, The University Of Texas System | Liposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and use |
FR2710074B1 (fr) | 1993-09-15 | 1995-12-08 | Rhone Poulenc Rorer Sa | Gène GRB3-3, ses variants et leurs utilisations. |
ATE164515T1 (de) * | 1993-11-05 | 1998-04-15 | Amgen Inc | Herstellung von liposomen und verfahren zur substanzverkapselung |
US5651981A (en) | 1994-03-29 | 1997-07-29 | Northwestern University | Cationic phospholipids for transfection |
US5696248A (en) | 1994-06-15 | 1997-12-09 | Hoechst Aktiengesellschaft | 3'-modified oligonucleotide derivatives |
US5908635A (en) * | 1994-08-05 | 1999-06-01 | The United States Of America As Represented By The Department Of Health And Human Services | Method for the liposomal delivery of nucleic acids |
IT1275862B1 (it) * | 1995-03-03 | 1997-10-24 | Consiglio Nazionale Ricerche | Trascritto antisenso associato ad alcuni tipi di cellule tumorali ed oligodeossinucleotidi sintetici utili nella diagnosi e nel trattamento |
EP0739898B1 (de) * | 1995-03-13 | 2001-09-26 | Aventis Pharma Deutschland GmbH | Phosphonomonoesternnukleinsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung |
DE69636339T2 (de) | 1995-06-01 | 2007-07-19 | Kishimoto, Tadamitsu, Tondabayashi | Wachstumsinhibitor gegen leukämische zellen, der antisense-oligonukleotidderivate gegen das wilms-tumorgen enthält |
US6326487B1 (en) | 1995-06-05 | 2001-12-04 | Aventis Pharma Deutschland Gmbh | 3 modified oligonucleotide derivatives |
US5756122A (en) * | 1995-06-07 | 1998-05-26 | Georgetown University | Liposomally encapsulated nucleic acids having high entrapment efficiencies, method of manufacturer and use thereof for transfection of targeted cells |
US5705385A (en) | 1995-06-07 | 1998-01-06 | Inex Pharmaceuticals Corporation | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
IL122290A0 (en) | 1995-06-07 | 1998-04-05 | Inex Pharmaceuticals Corp | Lipid-nucleic acid complex its preparation and use |
ATE247971T1 (de) * | 1995-08-01 | 2003-09-15 | Novartis Erfind Verwalt Gmbh | Liposomale oligonukleotidzusammensetzungen |
US5855911A (en) * | 1995-08-29 | 1999-01-05 | Board Of Regents, The University Of Texas System | Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides |
DE19532553A1 (de) * | 1995-09-04 | 1997-03-06 | Hoechst Ag | Verfahren zur Herstellung substituierter N-Ethyl-Glycinderivate |
US6120794A (en) | 1995-09-26 | 2000-09-19 | University Of Pittsburgh | Emulsion and micellar formulations for the delivery of biologically active substances to cells |
US6977244B2 (en) * | 1996-10-04 | 2005-12-20 | Board Of Regents, The University Of Texas Systems | Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides |
US5874224A (en) | 1997-03-11 | 1999-02-23 | Incyte Pharmaceuticals, Inc. | Growth factor receptor binding protein |
US6126965A (en) | 1997-03-21 | 2000-10-03 | Georgetown University School Of Medicine | Liposomes containing oligonucleotides |
GB9711919D0 (en) | 1997-06-09 | 1997-08-06 | Ciba Geigy Ag | Oligonucleotide derivatives |
TWI225412B (en) | 1997-06-23 | 2004-12-21 | Sequus Pharm Inc | Liposome-entrapped polynucleotide composition and method |
WO1999001139A1 (en) | 1997-07-03 | 1999-01-14 | Thomas Jefferson University | An improved method for design and selection of efficacious antisense oligonucleotides |
US7285288B1 (en) * | 1997-10-03 | 2007-10-23 | Board Of Regents, The University Of Texas System | Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides |
US6136965A (en) | 1998-07-02 | 2000-10-24 | The Regents Of The University Of California | Deoxynucleic alkyl and alkoxy thiourea compounds |
US6211162B1 (en) | 1998-12-30 | 2001-04-03 | Oligos Etc. Inc. | Pulmonary delivery of protonated/acidified nucleic acids |
US6211349B1 (en) | 1998-12-30 | 2001-04-03 | Oligos Etc., Inc. | Protonated/acidified nucleic acids and methods of use |
US7795232B1 (en) | 2000-08-25 | 2010-09-14 | Genta Incorporated | Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers |
-
1995
- 1995-08-29 US US08/520,385 patent/US5855911A/en not_active Expired - Lifetime
-
1996
- 1996-08-26 EP EP96929888A patent/EP0847272B1/en not_active Expired - Lifetime
- 1996-08-26 AT AT96929888T patent/ATE253897T1/de not_active IP Right Cessation
- 1996-08-26 AU AU69129/96A patent/AU6912996A/en not_active Abandoned
- 1996-08-26 CA CA2228944A patent/CA2228944C/en not_active Expired - Fee Related
- 1996-08-26 DE DE69630691T patent/DE69630691T2/de not_active Expired - Lifetime
- 1996-08-26 PT PT96929888T patent/PT847272E/pt unknown
- 1996-08-26 DK DK96929888T patent/DK0847272T3/da active
- 1996-08-26 JP JP51064297A patent/JP4291412B2/ja not_active Expired - Fee Related
- 1996-08-26 ES ES96929888T patent/ES2210385T3/es not_active Expired - Lifetime
- 1996-08-26 WO PCT/US1996/014146 patent/WO1997007784A2/en active IP Right Grant
-
1998
- 1998-07-09 US US09/112,869 patent/US6042846A/en not_active Expired - Lifetime
-
2003
- 2003-06-16 US US10/462,172 patent/US7176302B2/en not_active Expired - Fee Related
-
2007
- 2007-02-13 US US11/674,563 patent/US7754872B2/en not_active Expired - Fee Related
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008536874A (ja) * | 2005-04-15 | 2008-09-11 | ボード オブ リージェンツ ザ ユニバーシティー オブ テキサス システム | 中性脂質組成物によるsiRNAの送達 |
JP2009535384A (ja) * | 2006-05-03 | 2009-10-01 | サントル ナシオナル ドゥ ラ ルシェルシェサイアンティフィク(セエヌエールエス) | リポソームの即時的および可逆的濃縮のための方法 |
US9895298B2 (en) | 2006-05-03 | 2018-02-20 | Centre National De La Recherche Scientifique (C.N.R.S.) | Method for extemporaneous and reversible concentration of liposomes |
JP2018534361A (ja) * | 2015-10-14 | 2018-11-22 | バイオ−パス ホールディングス, インコーポレイテッド | リポソーム製剤のためのp−エトキシ核酸 |
JP2022027993A (ja) * | 2015-10-14 | 2022-02-14 | バイオ-パス ホールディングス, インコーポレイテッド | リポソーム製剤のためのp-エトキシ核酸 |
JP2020517632A (ja) * | 2017-04-19 | 2020-06-18 | バイオ−パス ホールディングス, インコーポレイテッド | Stat3阻害のためのp−エトキシ核酸 |
JP2020517631A (ja) * | 2017-04-19 | 2020-06-18 | バイオ−パス ホールディングス, インコーポレイテッド | Igf−1r阻害のためのp−エトキシ核酸 |
Also Published As
Publication number | Publication date |
---|---|
DK0847272T3 (da) | 2004-03-22 |
CA2228944A1 (en) | 1997-03-06 |
WO1997007784A2 (en) | 1997-03-06 |
ATE253897T1 (de) | 2003-11-15 |
US5855911A (en) | 1999-01-05 |
DE69630691D1 (de) | 2003-12-18 |
US6042846A (en) | 2000-03-28 |
CA2228944C (en) | 2011-10-18 |
US7176302B2 (en) | 2007-02-13 |
AU6912996A (en) | 1997-03-19 |
ES2210385T3 (es) | 2004-07-01 |
EP0847272A2 (en) | 1998-06-17 |
US20040005353A1 (en) | 2004-01-08 |
EP0847272B1 (en) | 2003-11-12 |
PT847272E (pt) | 2004-04-30 |
WO1997007784A3 (en) | 1997-04-24 |
JP4291412B2 (ja) | 2009-07-08 |
US7754872B2 (en) | 2010-07-13 |
US20070202157A1 (en) | 2007-08-30 |
DE69630691T2 (de) | 2004-11-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH11512099A (ja) | リポソーマルホスホジエステル、ホスホロチオエート、およびp−エトキシオリゴヌクレオチド | |
US5665710A (en) | Method of making liposomal oligodeoxynucleotide compositions | |
EP0711149B1 (en) | Liposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and use | |
US5851548A (en) | Liposomes containing cationic lipids and vitamin D | |
AU2009330859B2 (en) | Pharmaceutical composition containing an anionic drug, and a production method therefor | |
JPH11511128A (ja) | リポソームオリゴヌクレオチド組成物 | |
JPH09500136A (ja) | 樹枝状体ポリ陽イオンを含む自己集合性ポリヌクレオチド配送系 | |
US9532950B2 (en) | Vector for pulmonary delivery, inducing agent, and uses | |
US5739271A (en) | Thiocationic lipids | |
CN113164768B (zh) | 用于抑制tmprss6表达的核酸和铁螯合剂 | |
JP2022506503A (ja) | 修飾二重鎖オリゴヌクレオチド | |
US8598138B2 (en) | Amphiphilic nucleotide cochleate compositions and methods of using the same | |
KR101678327B1 (ko) | 약산성 pH 응답성 펩티드 및 상기 펩티드를 포함하는 리포솜 | |
AU5862296A (en) | Thiocationic lipids, pharmaceutical compositions and methods of use thereof | |
US5759519A (en) | Method for the intracellular delivery of biomolecules using thiocationic lipids | |
US5756352A (en) | Thiocationic lipid-nucleic acid conjugates | |
Tari et al. | Oligonucleotide therapy for hematological malignancies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20071120 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080220 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080331 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080520 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080805 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20081105 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20081215 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090121 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20090310 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20090403 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120410 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120410 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130410 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140410 Year of fee payment: 5 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |